Resistance to dual blockade of the kinases PI3K and mTOR in KRAS-mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFR

Science Signaling

Volumn 7, Issue 351, 2014, Pages

  Belmont, Peter J ^a   Jiang, Ping ^a   McKee, Trevor D ^b   Xie, Tao ^a   Isaacson, Jason ^a   Baryla, Nicole E ^c   Roper, Jatin ^d   Sinnamon, Mark J ^d   Lee, Nathan V ^a   Kan, Julie L C ^a   Guicherit, Oivin ^a   Wouters, Bradly G ^b,c   O'Brien, Catherine A ^e   Shields, David ^a   Olson, Peter ^a   Van Arsdale, Todd ^a   Weinrich, Scott L ^a   Rejto, Paul ^a   Christensen, James G ^a   Fantin, Valeria R ^a   Hung, Kenneth E ^f   Martin, Eric S ^a,g   more..

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c ONTARIO INSTITUTE FOR CANCER RESEARCH   (Canada)

^d TUFTS MEDICAL CENTER   (United States)

^e UNIVERSITY HEALTH NETWORK   (Canada)

^f PFIZER INC   (United States)

^g Ignyta   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 8 [4 (2 HYDROXYETHOXY)CYCLOHEXYL] 6 (6 METHOXY 3 PYRIDINYL) 4 METHYLPYRIDO[2,3 D]PYRIMIDIN 7(8H) ONE; DACOMITINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; K RAS PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; TRANSCRIPTION FACTOR FKHRL1; BETA CATENIN; ENZYME INHIBITOR; PROTEIN P53; RAS PROTEIN; TARGET OF RAPAMYCIN KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER REGRESSION; CANCER RESISTANCE; COLORECTAL CANCER; CONTROLLED STUDY; DRUG EFFICACY; DRUG SENSITIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; IC50; MOUSE; NONHUMAN; PROTEIN PHOSPHORYLATION; RNA SEQUENCE; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; CANCER TRANSPLANTATION; CELL PROLIFERATION; CELL SEPARATION; CELL SURVIVAL; CHEMISTRY; COLORECTAL TUMOR; DISEASE MODEL; DRUG RESISTANCE; FEMALE; FLOW CYTOMETRY; GENETIC ENGINEERING; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; MUTATION; ONCOGENE RAS; PHOSPHORYLATION; SCID MOUSE; TUMOR CELL LINE;

ANIMALS; BETA CATENIN; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SEPARATION; CELL SURVIVAL; COLORECTAL NEOPLASMS; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; FEMALE; FLOW CYTOMETRY; GENES, RAS; GENETIC ENGINEERING; HUMANS; MICE; MICE, SCID; MUTATION; NEOPLASM TRANSPLANTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84910642311     PISSN: 19450877     EISSN: 19379145     Source Type: Journal    
DOI: 10.1126/scisignal.2005516     Document Type: Article

References (62)

1. D. E. Gerber, Targeted therapies: A new generation of cancer treatments. Am. Fam. Physician 77, 311-319 (2008).
2. Z. A. Knight, H. Lin, K. M. Shokat, Targeting the cancer kinome through polypharmacology. Nat. Rev. Cancer 10, 130-137 (2010).
3. A. Hochhaus, Imatinib mesylate (Glivec, Gleevec) in the treatment of chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST). Ann. Hematol. 83 (Suppl. 1), S65-S66 (2004).
4. M. A. Cobleigh, C. L. Vogel, D. Tripathy, N. J. Robert, S. Scholl, L. Fehrenbacher, J. M. Wolter, V. Paton, S. Shak, G. Lieberman, D. J. Slamon, Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol. 17, 2639-2648 (1999).
5. P. B. Chapman, A. Hauschild, C. Robert, J. B. Haanen, P. Ascierto, J. Larkin, R. Dummer, C. Garbe, A. Testori, M. Maio, D. Hogg, P. Lorigan, C. Lebbe, T. Jouary, D. Schadendorf, A. Ribas, S. J. O'Day, J. A. Sosman, J. M. Kirkwood, A. M. Eggermont, B. Dreno, K. Nolop, J. Li, B. Nelson, J. Hou, R. J. Lee, K. T. Flaherty, G. A. McArthur; BRIM-3 Study Group, Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507-2516 (2011).
6. E. L. Kwak, Y. J. Bang, D. R. Camidge, A. T. Shaw, B. Solomon, R. G. Maki, S. H. Ou, B. J. Dezube, P. A. Jänne, D. B. Costa, M. Varella-Garcia, W. H. Kim, T. J. Lynch, P. Fidias, H. Stubbs, J. A. Engelman, L. V. Sequist, W. Tan, L. Gandhi, M. Mino-Kenudson, G. C. Wei, S. M. Shreeve, M. J. Ratain, J. Settleman, J. G. Christensen, D. A. Haber, K. Wilner, R. Salgia, G. I. Shapiro, J. W. Clark, A. J. Iafrate, Anaplastic lymphoma kinase inhibition in non - small-cell lung cancer. N. Engl. J. Med. 363, 1693-1703 (2010).
7. M. R. Lackner, T. R. Wilson, J. Settleman, Mechanisms of acquired resistance to targeted cancer therapies. Future Oncol. 8, 999-1014 (2012).
8. C. Holohan, S. Van Schaeybroeck, D. B. Longley, P. G. Johnston, Cancer drug resistance: An evolving paradigm. Nat. Rev. Cancer 13, 714-726 (2013).
9. L. A. Garraway, P. A. Jänne, Circumventing cancer drug resistance in the era of personalized medicine. Cancer Discov. 2, 214-226 (2012).
10. S. Chandarlapaty, Negative feedback and adaptive resistance to the targeted therapy of cancer. Cancer Discov. 2, 311-319 (2012).
11. K. Moitra, H. Lou, M. Dean, Multidrug efflux pumps and cancer stem cells: Insights into multidrug resistance and therapeutic development. Clin. Pharmacol. Ther. 89, 491-502(2011).
12. J. W. Locasale, Metabolic rewiring drives resistance to targeted cancer therapy. Mol. Syst. Biol. 8, 597 (2012).
13. S. V. Sharma, D. Y. Lee, B. Li, M. P. Quinlan, F. Takahashi, S. Maheswaran, U. McDermott, N. Azizian, L. Zou, M. A. Fischbach, K. K. Wong, K. Brandstetter, B. Wittner, S. Ramaswamy, M. Classon, J. Settleman, A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141, 69-80 (2010).
14. F. Crea, S. Nobili, E. Paolicchi, G. Perrone, C. Napoli, I. Landini, R. Danesi, E. Mini, Epigenetics and chemoresistance in colorectal cancer: An opportunity for treatment tailoring and novel therapeutic strategies. Drug Resist. Updat. 14, 280-296 (2011).
15. M. P. Morelli, J. J. Tentler, G. N. Kulikowski, A. C. Tan, E. L. Bradshaw-Pierce, T. M. Pitts, A. M. Brown, S. Nallapareddy, J. J. Arcaroli, N. J. Serkova, M. Hidalgo, F. Ciardiello, S. G. Eckhardt, Preclinical activity of the rational combination of selumetinib (AZD6244) in combination with vorinostat in KRAS-mutant colorectal cancer models. Clin. Cancer Res. 18, 1051-1062 (2012).
16. T. Arumugam, V. Ramachandran, K. F. Fournier, H. Wang, L. Marquis, J. L. Abbruzzese, G. E. Gallick, C. D. Logsdon, D. J. McConkey, W. Choi, Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res. 69, 5820-5828 (2009).
17. F. Fan, S. Samuel, P. Gaur, J. Lu, N. A. Dallas, L. Xia, D. Bose, V. Ramachandran, L. M. Ellis, Chronic exposure of colorectal cancer cells to bevacizumab promotes compensatory pathways that mediate tumour cell migration. Br. J. Cancer 104, 1270-1277 (2011).
18. A. D. Yang, F. Fan, E. R. Camp, G. van Buren, W. Liu, R. Somcio, M. J. Gray, H. Cheng, P. M. Hoff, L. M. Ellis, Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines. Clin. Cancer Res. 12, 4147-4153 (2006).
19. A. Singh, J. Settleman, EMT, cancer stem cells and drug resistance: An emerging axis of evil in the war on cancer. Oncogene 29, 4741-4751 (2010).
20. N. A. Dallas, L. Xia, F. Fan, M. J. Gray, P. Gaur, G. van Buren Jr., S. Samuel, M. P. Kim, S. J. Lim, L. M. Ellis, Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition. Cancer Res. 69, 1951-1957 (2009).
21. I. B. Weinstein, A. K. Joe, Mechanisms of disease: Oncogene addiction - A rationale for molecular targeting in cancer therapy. Nat. Clin. Pract. Oncol. 3, 448-457 (2006).
22. I. B. Weinstein, Cancer. Addiction to oncogenes - The Achilles heel of cancer. Science 297, 63-64 (2002).
23. S. V. Sharma, J. Settleman, Oncogene addiction: Setting the stage for molecularly targeted cancer therapy. Genes Dev. 21, 3214-3231 (2007).
24. J. Downward, Targeting RAS signalling pathways in cancer therapy. Nat. Rev. Cancer 3, 11-22 (2003).
25. K. Suda, K. Tomizawa, T. Mitsudomi, Biological and clinical significance of KRAS mutations in lung cancer: An oncogenic driver that contrasts with EGFR mutation. Cancer Metastasis Rev. 29, 49-60 (2010).
26. E. Castellano, J. Downward, RAS interaction with PI3K: More than just another effector pathway. Genes Cancer 2, 261-274 (2011).
27. J. A. Fresno Vara, E. Casado, J. de Castro, P. Cejas, C. Belda-Iniesta, M. González-Barón, PI3K/Akt signalling pathway and cancer. Cancer Treat. Rev. 30, 193-204 (2004).
28. B. T. Hennessy, D. L. Smith, P. T. Ram, Y. Lu, G. B. Mills, Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat. Rev. Drug Discov. 4, 988-1004 (2005).
29. J. Rodon, R. Dienstmann, V. Serra, J. Tabernero, Development of PI3K inhibitors: Lessons learned from early clinical trials. Nat. Rev. Clin. Oncol. 10, 143-153 (2013).
30. J. Yuan, P. P. Mehta, M. J. Yin, S. Sun, A. Zou, J. Chen, K. Rafidi, Z. Feng, J. Nickel, J. Engebretsen, J. Hallin, A. Blasina, E. Zhang, L. Nguyen, M. Sun, P. K. Vogt, A. McHarg, H. Cheng, J. G. Christensen, J. L. Kan, S. Bagrodia, PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity. Mol. Cancer Ther. 10, 2189-2199 (2011).
31. E. S. Martin, P. J. Belmont, M. J. Sinnamon, L. G. Richard, J. Yuan, E. M. Coffee, J. Roper, L. Lee, P. Heidari, S. Y. Lunt, G. Goel, X. Ji, Z. Xie, T. Xie, J. Lamb, S. L. Weinrich, T. VanArsdale, R. T. Bronson, R. J. Xavier, M. G. Vander Heiden, J. L. Kan, U. Mahmood, K. E. Hung, Development of a colon cancer GEMM-derived orthotopic transplant model for drug discovery and validation. Clin. Cancer Res. 19, 2929-2940 (2013).
32. S. Chandarlapaty, A. Sawai, M. Scaltriti, V. Rodrik-Outmezguine, O. Grbovic-Huezo, V. Serra, P. K. Majumder, J. Baselga, N. Rosen, AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 19, 58-71 (2011).
33. S. P. Tenbaum, P. Ordóñez-Morán, I. Puig, I. Chicote, O. Arqués, S. Landolfi, Y. Fernández, J. R. Herance, J. D. Gispert, L. Mendizabal, S. Aguilar, S. Ramón y Cajal, S. Schwartz Jr., A. Vivancos, E. Espín, S. Rojas, J. Baselga, J. Tabernero, A. Muñoz, H. G. Palmer, β-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer. Nat. Med. 18, 892-901 (2012).
34. Y. Zhao, Y. Wang, W. G. Zhu, Applications of post-translational modifications of FoxO family proteins in biological functions. J. Mol. Cell. Biol. 3, 276-282 (2011).
35. C. S. Karapetis, S. Khambata-Ford, D. J. Jonker, C. J. O'Callaghan, D. Tu, N. C. Tebbutt, R. J. Simes, H. Chalchal, J. D. Shapiro, S. Robitaille, T. J. Price, L. Shepherd, H. J. Au, C. Langer, M. J. Moore, J. R. Zalcberg, K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 359, 1757-1765 (2008).
36. A. J. Gonzales, K. E. Hook, I. W. Althaus, P. A. Ellis, E. Trachet, A. M. Delaney, P. J. Harvey, T. A. Ellis, D. M. Amato, J. M. Nelson, D. W. Fry, T. Zhu, C.M. Loi, S. A. Fakhoury, K. M. Schlosser, K. E. Sexton, R. T. Winters, J. E. Reed, A. J. Bridges, D. J. Lettiere, D. A. Baker, J. Yang, H. T. Lee, H. Tecle, P. W. Vincent, Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor. Mol. Cancer Ther. 7, 1880-1889 (2008).
37. P. A. Jänne, D. S. Boss, D. R. Camidge, C. D. Britten, J. A. Engelman, E. B. Garon, F. Guo, S. Wong, J. Liang, S. Letrent, R. Millham, I. Taylor, S. G. Eckhardt, J.H. Schellens, Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors. Clin. Cancer Res. 17, 1131-1139 (2011).
38. J. S. Moreb, Aldehyde dehydrogenase as a marker for stem cells. Curr. Stem Cell Res. Ther. 3, 237-246 (2008).
39. T. Li, Y. Su, Y. Mei, Q. Leng, B. Leng, Z. Liu, S. A. Stass, F. Jiang, ALDH1A1 is a marker for malignant prostate stem cells and predictor of prostate cancer patients' outcome. Lab. Invest. 90, 234-244 (2010).
40. Y. Luo, K. Dallaglio, Y. Chen, W. A. Robinson, S. E. Robinson, M. D. McCarter, J. Wang, R. Gonzalez, D. C. Thompson, D. A. Norris, D. R. Roop, V. Vasiliou, M. Fujita, ALDH1A isozymes are markers of human melanoma stem cells and potential therapeutic targets. Stem Cells 30, 2100-2113 (2012).
41. M. P. Kim, J. B. Fleming, H. Wang, J. L. Abbruzzese, W. Choi, S. Kopetz, D. J. McConkey, D. B. Evans, G. E. Gallick, ALDH activity selectively defines an enhanced tumor-initiating cell population relative to CD133 expression in human pancreatic adenocarcinoma. PLOS One 6, e20636 (2011).
42. J. E. Carpentino, M. J. Hynes, H. D. Appelman, T. Zheng, D. A. Steindler, E. W. Scott, E. H. Huang, Aldehyde dehydrogenase - expressing colon stem cells contribute to tumorigenesis in the transition from colitis to cancer. Cancer Res. 69, 8208-8215 (2009).
43. Z. A. Rasheed, J. Yang, Q. Wang, J. Kowalski, I. Freed, C. Murter, S. M. Hong, J. B. Koorstra, N. V. Rajeshkumar, X. He, M. Goggins, C. Iacobuzio-Donahue, D. M. Berman, D. Laheru, A. Jimeno, M. Hidalgo, A. Maitra, W. Matsui, Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma. J. Natl. Cancer Inst. 102, 340-351 (2010).
44. C. Kahlert, E. Gaitzsch, G. Steinert, C. Mogler, E. Herpel, M. Hoffmeister, L. Jansen, A. Benner, H. Brenner, J. Chang-Claude, N. Rahbari, T. Schmidt, F. Klupp, N. Grabe, B. Lahrmann, M. Koch, N. Halama, M. Büchler, J. Weitz, Expression analysis of aldehyde dehydrogenase 1A1 (ALDH1A1) in colon and rectal cancer in association with prognosis and response to chemotherapy. Ann. Surg. Oncol. 19, 4193-4201 (2012).
45. N. E. Sládek, R. Kollander, L. Sreerama, D. T. Kiang, Cellular levels of aldehyde dehydrogenases (ALDH1A1 and ALDH3A1) as predictors of therapeutic responses to cyclophosphamide-based chemotherapy of breast cancer: A retrospective study. Rational individualization of oxazaphosphorine-based cancer chemotherapeutic regimens. Cancer Chemother. Pharmacol. 49, 309-321 (2002).
46. S. Deng, X. Yang, H. Lassus, S. Liang, S. Kaur, Q. Ye, C. Li, L. P. Wang, K. F. Roby, S. Orsulic, D. C. Connolly, Y. Zhang, K. Montone, R. Bützow, G. Coukos, L. Zhang, Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers. PLOS One 5, e10277 (2010).
47. T. Reya, H. Clevers, Wnt signalling in stem cells and cancer. Nature 434, 843-850 (2005).
48. L. Vermeulen, F. De Sousa E Melo, M. van der Heijden, K. Cameron, J. H. de Jong, T. Borovski, J. B. Tuynman, M. Todaro, C. Merz, H. Rodermond, M. R. Sprick, K. Kemper, D. J. Richel, G. Stassi, J. P. Medema, Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat. Cell Biol. 12, 468-476 (2010).
49. J. A. Engelman, J. Settleman, Acquired resistance to tyrosine kinase inhibitors during cancer therapy. Curr. Opin. Genet. Dev. 18, 73-79 (2008).
50. G. V. Hegde, C. C. de la Cruz, C. Chiu, N. Alag, G. Schaefer, L. Crocker, S. Ross, D. Goldenberg, M. Merchant, J. Tien, L. Shao, L. Roth, S. P. Tsai, S. Stawicki, Z. Jin, S. K. Wyatt, R. A. Carano, Y. Zheng, E. A. Sweet-Cordero, Y. Wu, E. L. Jackson, Blocking NRG1 and other ligand-mediated Her4 signaling enhances the magnitude and duration of the chemotherapeutic response of non - small cell lung cancer. Sci. Transl. Med. 5, 171ra18 (2013).
51. H. Piessevaux, M. Buyse, M. Schlichting, E. Van Cutsem, C. Bokemeyer, S. Heeger, S. Tejpar, Use of early tumor shrinkage to predict long-term outcome in metastatic colorectal cancer treated with cetuximab. J. Clin. Oncol. 31, 3764-3755 (2013).
52. G. Pentheroudakis, V. Kotoula, W. De Roock, G. Kouvatseas, P. Papakostas, T. Makatsoris, D. Papamichael, I. Xanthakis, J. Sgouros, D. Televantou, G. Kafiri, A. C. Tsamandas, E. Razis, E. Galani, D. Bafaloukos, I. Efstratiou, I. Bompolaki, D. Pectasides, N. Pavlidis, S. Tejpar, G. Fountzilas, Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: Interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes. BMC Cancer 13, 49 (2013).
53. R. G. Amado, M. Wolf, M. Peeters, E. Van Cutsem, S. Siena, D. J. Freeman, T. Juan, R. Sikorski, S. Suggs, R. Radinsky, S. D. Patterson, D. D. Chang, Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 26, 1626-1634 (2008).
54. S. Misale, S. Arena, S. Lamba, G. Siravegna, A. Lallo, S. Hobor, M. Russo, M. Buscarino, L. Lazzari, A. Sartore-Bianchi, K. Bencardino, A. Amatu, C. Lauricella, E. Valtorta, S. Siena, F. Di Nicolantonio, A. Bardelli, Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer. Sci. Transl. Med. 6, 224ra26 (2014).
55. T. R. Wilson, J. Fridlyand, Y. Yan, E. Penuel, L. Burton, E. Chan, J. Peng, E. Lin, Y. Wang, J. Sosman, A. Ribas, J. Li, J. Moffat, D. P. Sutherlin, H. Koeppen, M. Merchant, R. Neve, J. Settleman, Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 487, 505-509 (2012).
56. M. Dean, T. Fojo, S. Bates, Tumour stem cells and drug resistance. Nat. Rev. Cancer 5, 275-284 (2005).
57. J. M. Houthuijzen, L. G. Daenen, J. M. Roodhart, E. E. Voest, The role of mesenchymal stem cells in anti-cancer drug resistance and tumour progression. Br. J. Cancer 106, 1901-1906 (2012).
58. D. Bose, L. J. Zimmerman, M. Pierobon, E. Petricoin, F. Tozzi, A. Parikh, F. Fan, N. Dallas, L. Xia, P. Gaur, S. Samuel, D. C. Liebler, L. M. Ellis, Chemoresistant colorectal cancer cells and cancer stem cells mediate growth and survival of bystander cells. Br. J. Cancer 105, 1759-1767 (2011).
59. E. L. Abhold, A. Kiang, E. Rahimy, S. Z. Kuo, J. Wang-Rodriguez, J. P. Lopez, K. J. Blair, M. A. Yu, M. Haas, K. T. Brumund, X. Altuna, A. Patel, R. A. Weisman, W. M. Ongkeko, EGFR kinase promotes acquisition of stem cell-like properties: A potential therapeutic target in head and neck squamous cell carcinoma stem cells. PLOS One 7, e32459 (2012).
60. S. Singh, J. Trevino, N. Bora-Singhal, D. Coppola, E. Haura, S. Altiok, S. P. Chellappan, EGFR/Src/Akt signaling modulates Sox2 expression and self-renewal of stem-like sidepopulation cells in non-small cell lung cancer. Mol. Cancer 11, 73 (2012).
61. C. Trapnell, L. Pachter, S. L. Salzberg, TopHat: Discovering splice junctions with RNA-Seq. Bioinformatics 25, 1105-1111 (2009).
62. C. Trapnell, B. A. Williams, G. Pertea, A. Mortazavi, G. Kwan, M. J. van Baren, S. L. Salzberg, B. J. Wold, L. Pachter, Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat. Biotechnol. 28, 511-515 (2010).